(RTTNews) - Creative Medical Technology Holdings, Inc. (CELZ), a clinical-stage biotechnology company, issued a mid-year update from its President and CEO, Timothy Warbington.
Creative Medical focuses on developing regenerative medicine therapies derived from adult and perinatal stem cell technologies, and CELZ-201 (Olastrocel) is the company's lead clinical asset in development for chronic lower back pain. The company is currently advancing CELZ-201 toward Phase 3 readiness in chronic lower back pain.
The company's other core programs include Ultrasome Knee Osteoarthritis(OA) program and CELZ-Biodefense Platform.
The near-term milestones for Olastrocel, Ultrasome OA studies and CELZ-Biodefense Toxic Exposure Atlas highlighted by the company include,
-Complete enrollment of the expanded ADAPT cohort and to generate long-term follow-up data for Olastrocel.
-To interact with regulatory authorities to align on Phase 3 planning for chronic lower back pain.
-Initiation and readout of next-stage Ultrasome studies in osteoarthritis of the knee.
-Demonstration of initial AI-derived insights and partnership interest related to the CELZ-Biodefense Toxic Exposure Atlas, which is a regulator-approved burn pit program and AI-enabled to generate integrated datasets for toxic exposure, supporting future drug, biologic, biotherapeutic, and regenerative therapy discovery.
CELZ has traded between $0.79 and $ 6.25 over the last year. The stock closed Tuesday's trade at $1.45.
CELZ is currently down 11.72% at $1.28.
For More Such Biotech Stock News, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
